ArticleBMC cardiovascular disorders2025
Benefits and risks of sleep medication in individuals with hypertension and sleep disturbance: evidence from a large population-based study.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe benefits and risks of sleep medications among patients with hypertension and sleep disturbance remain unclear. This study aims to investigate the potential benefits and risks of sleep medications in this population.
methodsThis was a prospective cohort study among US adults, using hypertension and medication data from the National Health and Nutrition Examination Survey (NHANES). Linear regression assessed the efficacy of sleep medications in controlling blood pressure. Cox regression explored associations between sleep medications and mortality.
resultsThis study included 4836 participants taking antihypertensive medication with sleep disturbance. Compared with non-users, benzodiazepine users had an adjusted estimated systolic blood pressure (SBP) difference of -2.22 mmHg (95% CI, -3.70 to -0.74; P = 0.003), while benzodiazepine-like agents (Z-drugs) users had a more pronounced difference of -3.33 mmHg (95% CI, -5.85 to -0.81; P = 0.010), with diazepam, clonazepam, and zolpidem demonstrating significant antihypertensive effects. The median follow-up time was 82.3 months, and 809 all-cause deaths occurred. Sleep medications (hazard ratio [HR]: 1.14; 95% CI, 0.97 to 1.33; P = 0.120) and benzodiazepine users (HR: 1.05; 95% CI, 0.87 to 1.26; P = 0.639) were not associated with an increased risk of all-cause mortality, while Z-drug users were linked to a higher risk (HR: 1.39; 95% CI, 1.04 to 1.85; P = 0.025) compared to non-users. No significant association was found with cardiovascular mortality.
conclusionsSleep medication use is associated with lower blood pressure and is not significantly associated with an elevated mortality risk among hypertensive participants with sleep disturbance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.